191 related articles for article (PubMed ID: 35173413)
1. Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease.
Venkateswaran N; Bian Y; Gupta PK
Clin Ophthalmol; 2022; 16():349-355. PubMed ID: 35173413
[TBL] [Abstract][Full Text] [Related]
2. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares.
Gupta PK; Venkateswaran N
Ther Adv Ophthalmol; 2021; 13():25158414211012797. PubMed ID: 34017938
[TBL] [Abstract][Full Text] [Related]
3. Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease.
Paton DM
Drugs Today (Barc); 2022 Feb; 58(2):77-84. PubMed ID: 35188142
[TBL] [Abstract][Full Text] [Related]
4. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.
Schopf L; Enlow E; Popov A; Bourassa J; Chen H
Ophthalmol Ther; 2014 Dec; 3(1-2):63-72. PubMed ID: 25134493
[TBL] [Abstract][Full Text] [Related]
5. Loteprednol Etabonate for the Treatment of Dry Eye Disease.
Beckman K; Katz J; Majmudar P; Rostov A
J Ocul Pharmacol Ther; 2020 Sep; 36(7):497-511. PubMed ID: 32391735
[TBL] [Abstract][Full Text] [Related]
6. The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye.
Hovanesian JA; Keyser A; Berdy G; Sorensen R
Clin Ophthalmol; 2022; 16():3841-3849. PubMed ID: 36438591
[TBL] [Abstract][Full Text] [Related]
7. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
Lyseng-Williamson KA
Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
[TBL] [Abstract][Full Text] [Related]
8. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
Noble S; Goa KL
BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
[TBL] [Abstract][Full Text] [Related]
9. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
Kang C; Keam SJ; Shirley M; Syed YY
Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
[TBL] [Abstract][Full Text] [Related]
10. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
11. Effects of corneal nerve density on the response to treatment in dry eye disease.
Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
[TBL] [Abstract][Full Text] [Related]
12. Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated With Graft-versus-Host Disease.
Yin J; Kheirkhah A; Dohlman T; Saboo U; Dana R
Am J Ophthalmol; 2018 Jun; 190():17-23. PubMed ID: 29572107
[TBL] [Abstract][Full Text] [Related]
13. Dry Eye Disease as a Cause of Refractive Errors After Cataract Surgery - A Systematic Review.
Biela K; Winiarczyk M; Borowicz D; Mackiewicz J
Clin Ophthalmol; 2023; 17():1629-1638. PubMed ID: 37304333
[TBL] [Abstract][Full Text] [Related]
14. [Study on the treatment of dry eye with Loteprednol Etabonate].
Wan PX; Wang XR; Song YY; Li ZY; Duan HC; Zhang W; Liu Z; Wang ZC
Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):142-7. PubMed ID: 22490950
[TBL] [Abstract][Full Text] [Related]
15. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
Holland EJ; Djalilian AR; Sanderson JP
Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
[TBL] [Abstract][Full Text] [Related]
17. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
[TBL] [Abstract][Full Text] [Related]
18. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
Amon M; Busin M
Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
[TBL] [Abstract][Full Text] [Related]
19. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid.
Comstock TL; Sheppard JD
Expert Opin Pharmacother; 2018 Mar; 19(4):337-353. PubMed ID: 29430976
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
Holzer MP; Solomon KD; Sandoval HP; Vroman DT
J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]